Primary tumor

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Health, Oncology, COVID-19 testing, U.S. Securities and Exchange Commission, Physician, Central nervous system, Medical director, Twitter, Terminology, Risk, Spinal cord, Forward-looking statement, Neoplasm, Internet, Review, SEC, Banner, CSF, Security (finance), LMD, Private Securities Litigation Reform Act, Quality of life, Brain, Patient, Breast cancer, Biomarker, Cancer, COVID-19, Public health, HER2, Survival, Primary tumor, LinkedIn, Diagnosis, Cerebrospinal fluid, Poster, Life expectancy, Medical imaging

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).
  • The poster was chosen for a Spotlight Presentation at the San Antonio Breast Cancer Symposium on Dec. 8, 2021.
  • HER2-targeted treatment for patients with breast cancer and LMD may provide substantial survival advantages over the expected median survival of less than three months.
  • In this analysis, cerebrospinal fluid (CSF) of 63 patients with stage IV breast cancer and LMD was collected, and CSF tumor cells were captured and characterized using CNSide.

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

Retrieved on: 
Monday, November 15, 2021
Safety, Testicle, SITC, Molecular medicine, Cancer, Â, Therapy, Berlin, TCR, Cancer/testis antigens, SAN, Central tolerance, Technology, MAGE-A1, Program, Human, GLOBE, Primary tumor, CD8, Patient, Peptide, Vaccine, Pharmaceutical industry

SAN FRANCISCO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, reported preclinical data demonstrating that its novel MAGE-A1-specific T cell receptor (TCR) induced meaningful anti-tumor activity and enhanced engraftment as compared to human donor derived TCRs. In vivo data presented at the SITC annual meeting highlight the potential of T-knife’s lead product candidate TK-8001, a TCR engineered T cell therapy (TCR-T) that is being developed to treat MAGE-A1 positive solid tumors. The company plans to initiate a first-in-human, Phase 1/2 trial in early 2022.

Key Points: 
  • T-knife has used its proprietary HuTCR platform to discover multiple naturally optimized high-affinity TCRs specific for the cancer-testis antigen MAGE-A1.
  • These MAGE-A1-specific TCRs were isolated from the HuTCR platform and in vitro and in vivo activity were compared to different human-derived MAGE-A1-specific TCRs.
  • The data generated in these preclinical evaluations highlight the potential therapeutic benefit of TK-8001.
  • It is gratifying for our R&D team to present this exciting preclinical efficacy data in solid tumors expressing MAGE-A1, said Elisa Kieback, Ph.D., founder and Chief Technical Officer of T-knife Therapeutics.

Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors

Retrieved on: 
Monday, October 25, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pancreatic cancer, Blood, LinkedIn, Metastasis, Cancer, Travel, Annual report, Doctor of Philosophy, Drug development, Â, Neoplasm, Twitter, Security (finance), U.S. Securities and Exchange Commission, Kirom Bukhoroi, Patient, NASDAQ, Founder, Private Securities Litigation Reform Act, Terminology, SEC, Forward-looking statement, Primary tumor, Company, Clinical trial, Trial of the century, Tissue, Multimedia, Form 10-K, PFS, Securities Exchange Act of 1934, Pharmaceutical industry, Medical imaging, Vaccine, KiroVax/BSK01, Kiromic BioPharma, KIROVAX/BSK01, KIROMIC BIOPHARMA

We are very proud of the results we achieved with KiroVax/BSK01 in addressing advanced metastatic pancreatic cancer.

Key Points: 
  • We are very proud of the results we achieved with KiroVax/BSK01 in addressing advanced metastatic pancreatic cancer.
  • As we did with KiroVax/BSK01, we expect to be able to also progress Kiromics CAR-T therapies to the clinical arena.
  • Metastasis is the spread of cancer cells from the place where they first formed to another part of the body.
  • More information on this Phase 1 clinical trial may be found on the Companys website.

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Friday, October 1, 2021
Peptide, Therapy, Cancer, MAGE-A1, CD8, Primary tumor, TCR, Patient, Berlin, Central tolerance, Technology, Human, Molecular medicine, Safety, Cancer/testis antigens, Testicle, Vaccine

MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis.

Key Points: 
  • MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis.
  • T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens.
  • T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charit Universittsmedizin Berlin.
  • For additional information, please visit the companys website at www.t-knife.com .

Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma

Retrieved on: 
Monday, September 13, 2021
Cancer, TP53, Primary tumor, Food, SAN, Mutation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Osteosarcoma, FDA, DNA repair, EGFR, Patient, Company, Malignancy, Private Securities Litigation Reform Act, WEE1, RECIST, U.S. Securities and Exchange Commission, Risk, Clinical trial, EFS, SERD, Adult, Safety, Survival, DNA, Therapy, Pharmacokinetics, Bone, NSCLC, Cell death, GLOBE, Diagnosis, SEC, Large-cell lung carcinoma, Pharmaceutical industry

Zentalis recently received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration for pediatric osteosarcoma.

Key Points: 
  • Zentalis recently received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration for pediatric osteosarcoma.
  • If ZN-c3 were to obtain approval for the designated indication, it could potentially be eligible for a rare pediatric disease priority voucher upon approval.
  • The Phase 1/2 trial (ZN-c3-003) is a dose escalation and dose expansion study, evaluating the clinical activity, safety, pharmacodynamics and pharmacokinetics of ZN-c3 in combination with gemcitabine in relapsed or refractory osteosarcoma.
  • Even though curative therapy is available for the primary tumor, long-term outcomes for osteosarcoma patients continue to be impacted by metastatic progression.

Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference

Retrieved on: 
Tuesday, February 25, 2020
Oncology, Health, Research, Science, Pharmaceutical, Optical, Biotechnology, Medicine, Clinical medicine, Cancer, Antineoplastic drugs, Cancer treatments, Oncology, Drugs, Targeted therapy, Chemotherapy, Primary tumor

Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern Time in Boston, MA.

Key Points: 
  • Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern Time in Boston, MA.
  • The Companys proprietary technology platform utilizes viral-like particle bioconjugates (VPBs) that have a dual selectivity mechanism with targeted binding to cancer cells, followed by activation using a common laser.
  • These potent cytotoxic therapies result in acute tumor cell necrosis, while sparing surrounding healthy tissue and activating the immune system to generate an anti-tumor response.
  • The development of AU-011 is partially supported by funding awarded under a CRADA from the U.S. National Institutes of Healths National Cancer Institute.